Essential phospholipids, capsules 300 mg 30 pcs

Pharmacotherapeutic group:
Hepatoprotective agent
ATC:
A.05.C Drug combination for the treatment of liver and biliary tract diseases

Pharmacodynamics:
Essential phospholipids are basic structures of the cell membrane and cellular organelles.

In liver diseases there is always damage of liver cell membranes and their organelles, which leads to disorders of activity of associated enzymes and receptor systems, impaired functional activity of liver cells and decreased ability to regenerate.

Phospholipids contained in the preparation correspond in their chemical structure to endogenous phospholipids but exceed endogenous phospholipids in activity, due to their higher content of polyunsaturated (essential) fatty acids. The incorporation of these high-energy molecules into the damaged parts of hepatocyte cell membranes restores the integrity of hepatic cells and promotes their regeneration. Cis-double bonds of their polyunsaturated fatty acids prevent parallel arrangement of hydrocarbon chains in phospholipids of cell membranes, phospholipid structure of hepatocyte cell membranes “loosens up”, which causes increase of their fluidity and elasticity, improves metabolism. The formed functional blocks increase the activity of membrane-fixed enzymes and contribute to the normal physiological way of most important metabolic processes.

Phospholipids contained in the drug regulate the metabolism of lipoproteins, transferring neutral fats and cholesterol to the places of oxidation, mainly by increasing the ability of high density lipoproteins to bind to cholesterol.

Thus, there is a normalizing effect on lipid and protein metabolism, on the liver detoxifying function, on restoration and preservation of the liver cellular structure and phospholipid-dependent enzyme systems, which ultimately prevents the formation of connective tissue in the liver and promotes natural regeneration of liver cells.

With the excretion of phospholipids into the bile there is a decrease in the lithogenic index and stabilization of bile.

Pharmacokinetics:
More than 90% of the phospholipids taken orally are absorbed in the small intestine. Most of them are broken down by phospholipase A to 1-acyl-lysophosphatidylcholine, 50% of which immediately undergoes reverse acetylation to polyunsaturated phosphatidylcholine during the absorption process in the intestinal mucosa. This polyunsaturated phosphatidylcholine reaches the bloodstream with lymph and from there mainly in the form bound to high density lipoproteins enters the liver.

Pharmacokinetics studies in humans were conducted with dilinoleyl phosphatidylcholine with radioactive labeling (3H and 14C). The choline portion was labeled with 3H and the linoleic acid residue had 14C as a label.

The maximum concentration of 3H is reached 6-24 hours after administration and is 19.9% of the administered dose. The half-life of the choline component is 66 hours.

The maximum concentration of 14C is reached 4-12 hours after administration and is up to 27.9% of the administered dose. The half-life of this component is 32 hours. In the feces 2% of the administered dose of 3H and 4.5% of the administered dose of 14C are detected, in the urine – 6% of 3H and only minimal amounts of 14C.

Both isotopes are more than 90% absorbed in the intestine.

Indications

Composition

Directions for use

Contraindications

Pregnancy use